Log in to search using one of your social media accounts:

 

Endologix CEO McDermott to step down; shares slide -10% on Q4 results | Personnel Moves for Feb. 22, 2018
Endologix (NSDQ:ELGX) CEO John McDermott is planning to step down once an appropriate replacement is found, the company said yesterday as it announced fourth-quarter results that handily topped earnings expectations but missed on the top line. “Despite the business challenges over the past couple of years, I am confident that Endologix has a bright future. Our vision is clear, the value proposition is compelling, and our pipeline of new products positions us for significant long-term growth. I remain deeply committed to our employees, physicians, and patients and will do whatever I can to support an effective le...
Source: Mass Device - February 22, 2018 Category: Medical Devices Authors: Brad Perriello Tags: MassDevice Earnings Roundup Stent Grafts Wall Street Beat attunemedical Biocoat Cardiovascular Systems Inc. Dynatronics Corp Endologix Medtronic personnel-moves Presbia Wound Management Technologies Source Type: news

Anika posts mixed Q4, FY17 results
Shares in Anika Therapeutics (NSDQ:ANIK) rose today after the company topped earnings expectations on Wall Street with its fourth quarter and full-year financial results, but missed sales estimates. The Bedford, Mass.-based company posted profits of $8.1 million, or 55¢ per share, on sales of $29.3 million for the 3 months ended Dec. 31, for bottom-line loss of -0.2% on sales growth of 2.3% compared with the same period last year. Get the full story at our sister site, Drug Delivery Business News. The post Anika posts mixed Q4, FY17 results appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - February 22, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations MassDevice Earnings Roundup Orthopedics Pharmaceuticals Wall Street Beat Anika Therapeutics Inc. Source Type: news

Insulet beats the Street with Q4, FY17 sales
Insulet (NSDQ:PODD) reported yesterday that the insulin delivery device-maker topped sales expectations on Wall Street for its fourth quarter and full-year financial results, but missed earnings estimates. The Billerica, Mass.-based company reeled in losses, posting -$6.9 million on sales of $130.5 million for the 3 months ended Dec. 31, for sales growth of 26% compared with the same period last year. Get the full story at our sister site, Drug Delivery Business News. The post Insulet beats the Street with Q4, FY17 sales appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - February 22, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations Pharmaceuticals Wall Street Beat Insulet Source Type: news

Novocure misses Q4 EPS by a penny, tops sales estimates
Shares in Novocure (NSDQ:NVCR) rose slightly today in premarket activity after the medical device maker met sales expectations, but missed earnings estimates on Wall Street with its fourth quarter and full-year financial results. The St. Helier, N.J.-based company reeled in losses this quarter, posting -$10.9 million on sales of $53.7 million for the 3 months ended Dec. 31, for sales growth of 78% compared with the same period last year. Get the full story at our sister site, Drug Delivery Business News. The post Novocure misses Q4 EPS by a penny, tops sales estimates appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - February 22, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations MassDevice Earnings Roundup Oncology Pharmaceuticals Wall Street Beat NovoCure Source Type: news

Tax cuts push Teleflex into the red as Q4 revenues miss
Teleflex (NYSE:TFX) put red ink into the ledger during the fourth quarter, thanks to a $108 million hit from the tax reforms enacted last year, and missed the consensus expectation for the top line. Wayne, Pa.-based Teleflex reported losses of -$42.7 million, or -91¢ per share, on sales of $595.1 million for the three months ended Dec. 31, 2017, for sales growth of 15.8% and profits of $61.1 million for Q4 2016. Adjusted to exclude the $107.9 million tax hit and other one-time items, earnings per share were $2.44, 4¢ ahead of the forecast on Wall Street, where analysts were looking for sales of $601.2 m...
Source: Mass Device - February 22, 2018 Category: Medical Devices Authors: Brad Perriello Tags: MassDevice Earnings Roundup Wall Street Beat Teleflex Source Type: news

Globus Medical posts Q4, 2017 earnings that beat The Street
Globus Medical (NYSE:GMED) today posted fourth quarter and full year 2017 earnings that beat the Street on both sales and earnings per share. The Audubon, Penn.-based company posted profits of $24.4 million, or 25¢ per share, on sales of $176 million for the 3 months ended December 31, for bottom-line growth of 0.3% while sales grew 16.1% compared with the same period last year. Adjusted to exclude one-time items, earnings per share were 38¢, just ahead of the 35¢ consensus on Wall Street where analysts were expecting to see sales of $166.5 million, which the company also topped. For the full year, Glob...
Source: Mass Device - February 21, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News MassDevice Earnings Roundup Wall Street Beat Globus Medical Source Type: news

UPDATE: Robotics delay pushes Medtronic down despite fiscal Q3 beats
Medtronic (NYSE:MDT) shares took a hit today after the world’s largest medical device maker said its robot-assisted surgery platform has fallen behind schedule, despite fiscal third-quarter results that topped the consensus forecast on Wall Street. Fridley, Minn.-based Medtronic had predicted first-in-human cases during the fiscal year ending in April, with a full launch following in fiscal 2019. But during a conference call with investors today discussing the Q3 numbers, chairman & CEO Omar Ishrak said the timetable has gotten longer. “We are enthusiastic about the development of our surgical robotics plat...
Source: Mass Device - February 20, 2018 Category: Medical Devices Authors: Brad Perriello Tags: MassDevice Earnings Roundup Wall Street Beat Medtronic Source Type: news

Obalon: Whistleblower ’ s allegations ‘ without merit ’
Obalon Therapeutics (NSDQ:OBLN) said today that a probe by its audit committee found that the whistleblower allegations that last month sundered a $35 million offering are “without merit.” In January the San Diego-based company terminated the offering after the whistleblower told its independent auditors, KPMG, of the allegations of improper revenue recognition during the fourth quarter. Obalon was looking to offer 5.5 million shares at $5.50 per share, for roughly $30.3 million plus an over-allotment worth another $4.5 million. Obalon said at the time that the allegations made it “infeasible fo...
Source: Mass Device - February 20, 2018 Category: Medical Devices Authors: Brad Perriello Tags: MassDevice Earnings Roundup Wall Street Beat Weight loss Obalon Therapeutics Source Type: news

Tax law hits Medtronic, but sales climb
Medtronic reported a third-quarter loss of nearly $1.4 billion on Tuesday as the med-tech giant was bruised by the new U.S. tax law. But overall performance for the quarter was in line with or ahead of Wall Street estimates. Reuters has an early report on the numbers from Medtronic (NYSE: MDT), which is legally based in Dublin but keeps its operational headquarters in Fridley. The company's net loss for the quarter, compared to an $81 million profit for the same period a year ago, was largely due… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 20, 2018 Category: Pharmaceuticals Authors: Mark Reilly Source Type: news

Medtronic ’ s Q3 beats expectations
Medtronic (NYSE:MDT) posted fiscal third-quarter results today that topped the consensus forecast on Wall Street, despite taking a $2.2 billion hit from last year’s tax reforms. The Fridley, Minn.-based medical device titan posted losses of -$1.39 billion, or -$1.03 per share, on sales of $7.37 billion for the three months ended Jan. 26, compared with profits of $821 million on sales growth of 1.2% compared with fiscal Q3 2017. Adjusted to exclude one-time items, earnings per share were $1.18, a penny ahead of The Street, where analysts were looking for sales of $7.20 billion. “Our results reflect a solid quart...
Source: Mass Device - February 20, 2018 Category: Medical Devices Authors: Brad Perriello Tags: MassDevice Earnings Roundup Wall Street Beat Medtronic Source Type: news

Partners HealthCare starts fiscal 2018 in the black
Partners HealthCare on Thursday reported that it had generated operating income of $115 million in its most recent quarter — a positive sign for the largest health system in the Bay State, which reported a loss during the same period a year ago. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 15, 2018 Category: Pharmaceuticals Authors: David L. Harris Source Type: news

Icon reports more expectation-beating results
Medtech, pharma and biotech development outsourcer Icon continues to beat the Street when it comes to its results. Dublin, Ireland–based Icon (Nasdaq:ICLR) said today that it earned $78.5 million, or $1.43 per share, off $455.1 million in sales for the fourth quarter ended Dec. 31, 2017 – up from $74.3 million, or $1.33 per share, in profits off $435.1 million in revenue for the same quarter a year before. Analysts on average had expected fourth-quarter profits of $1.42 per share off $454.6 million in revenue, according to Yahoo Finance. Get the full story on our sister site Medical Design & Outsourcin...
Source: Mass Device - February 15, 2018 Category: Medical Devices Authors: Chris Newmarker Tags: Business/Financial News News Well Outsourcing Wall Street Beat ICON plc Source Type: news

Acorda posts Q4 revenue beat, but misses EPS estimates
Shares in Acorda Therapeutics (NSDQ:ACOR) fell today after the biotech company met sales expectations on Wall Street with its fourth-quarter results, but missed EPS estimates. The Ardsley, N.Y.-based company posted a net loss of -$171 million on sales of $188.4 million for the 3 months ended Dec.31, for sales growth of 34% compared with the same period last year. In explaining the company’s quarterly loss, Acorda cited a $234 million charge associated with the termination of one of its Parkinson’s therapy programs and a $24 million charge linked with a clinical trial that failed to meet key endpo...
Source: Mass Device - February 15, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations MassDevice Earnings Roundup Pharmaceuticals Wall Street Beat Acorda Therapeutics Source Type: news

Cardiovascular Systems launches Diamondback 360 EL in the US, touts 1st patients treated
Cardiovascular Systems (NSDQ:CSII) said today it launched its FDA-cleared extended length Diamondback 360 peripheral orbital atherectomy device in the US and that the first commercial patients have been treated with the device. The first procedures were performed at the Detroit Medical Center Heart Hospital by Dr. Mahir Elder and at the Arkansas Heart Hospital by Dr. Ian Cawich and Dr. Vasili Lendel, the St. Paul, Minn.-based company said. “From a physician’s perspective, radial access is a viable alternative that allows us to minimize bleeding and avoid commonly diseased femoral arteries. Additionall...
Source: Mass Device - February 14, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Vascular Cardiovascular Systems Inc. Source Type: news

Mazor Robotics shares down despite Street-beating Q4, FY2017 earnings
Shares in Mazor Robotics (NSDQ:MZOR) have fallen slightly today despite the surgical robotics platform maker topping expectations on Wall Street with its fourth quarter and full fiscal year 2017 earnings. The Israel-based company posted profits of $437,000, or 1¢ per share, on sales of $19.1 million for the three months ended December 31, seeing a 110.2% swing from the red on the bottom-line while sales grew 36.4% when compared to the same period last year. Adjusted to exclude one-time items, earnings per share were 3¢, well ahead of the negative 15¢ per share consensus on Wall Street, where analysts we...
Source: Mass Device - February 14, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News MassDevice Earnings Roundup Wall Street Beat mazorrobotics Source Type: news

Fitbit Extends Its Reach in Healthcare
Fitbit is expanding its reach in healthcare through the proposed acquisition of Boston-based Twine Health, a connected health platform designed to help people manage chronic conditions, aid in lifestyle interventions like weight loss and smoking cessation, and make it easier for providers and patients to collaborate on health plans. Learn about key topics in the industry at the free Advanced Design and Manufacturing (ADM) Conference and Expo March 7-8, 2018, in Cleveland, OH.  The deal, which is set to close in the first quarter, would lay the foundation for San Francisco, CA-based Fitbit to expand its offerings ...
Source: MDDI - February 14, 2018 Category: Medical Devices Authors: Amanda Pedersen Tags: Digital Health Source Type: news

Fonar's revenue, income rise in 2nd quarter
MRI vendor Fonar announced an increase in revenue and income for its second...Read more on AuntMinnie.comRelated Reading: Fonar posts revenue increase in Q1 Fonar posts year-end revenue increases Fonar posts mixed Q2 results Fonar boosts revenues, profits in Q1 Fonar buys 3 companies (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - February 13, 2018 Category: Radiology Source Type: news

Why Pharma Needs to Understand Population Health
It ’s no secret that healthcare is under growing pressure to reduce the cost of care while improving quality. Linkage of payment for healthcare to the cost and quality delivered – the idea behind value-based payment frameworks – is the driving force behind today’s rapidly changing healthcare la ndscape.Such linkage will likely be achieved using a population health model, where a provider contracts to deliver designated services to specific quality targets at an agreed-upon ‘all-in’ price. The arrangement makes the contracting provider financially accountable for cost over-runs and qualit...
Source: EyeForPharma - February 12, 2018 Category: Pharmaceuticals Authors: Rita Numerof Source Type: news

Innoviva posts Street-beating Q4, FY17 earnings
Shares in Innoviva (NSDQ:INVA) rose today after the company topped expectations on Wall Street with its fourth quarter and full-year financial results. The Brisbane, Calif.-based company posted profits of $58.4 million, or 55¢ per share, on sales of $69.5 million for the 3 months ended Dec. 31, for bottom-line growth of 129% on sales growth of 59% compared with the same period last year. Get the full story at our sister site, Drug Delivery Business News. The post Innoviva posts Street-beating Q4, FY17 earnings appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - February 9, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations MassDevice Earnings Roundup Pharmaceuticals Respiratory Wall Street Beat Innoviva Source Type: news

Hologic beats The Street, sees profits grow in FY2018 Q1 results
Hologic (NSDQ:HOLX) today posted fiscal year 2018 first quarter earnings that beat analyst expectations on The Street, seeing its sales and profits grow over the same quarter during the previous year. The Marlborough, Mass.-based company posted profits of $406.7 million, or $1.45 per share, on sales of $791.1 million for the three months ended December 30, seeing a massive 370.2% spike to the bottom line due to tax reform benefits while sales grew 7.7% compared with the same period during the previous year. Adjusted to exclude one-time items, earnings per share were 55¢, ahead of the 50¢ consensus on Wa...
Source: Mass Device - February 8, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News MassDevice Earnings Roundup Wall Street Beat Hologic Source Type: news

Teva shares tumble after “ challenging ” Q4, FY17
Shares in Teva Pharmaceuticals (NYSE:TEVA) fell today after the pharmaceutical company missed sales expectations on Wall Street with its fourth quarter results. The Israel-based company posted a net loss of -$11.6 billion, or -$11.43 per share, on sales of $5.46 billion for the 3 months ended Dec. 31, for a sales loss of -16% compared with the same period last year. Get the full story at our sister site, Drug Delivery Business News. The post Teva shares tumble after “challenging” Q4, FY17 appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - February 8, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: MassDevice Earnings Roundup Pharmaceuticals Wall Street Beat Teva Pharmaceuticals Source Type: news

ConforMIS shares down as Q4, FY2018 earnings show shrinking sales
Shares in ConforMIS (NSDQ:CFMS) have fallen slightly today after the medical device maker posted shrinking sales for its fourth quarter and full fiscal year 2017, despite having topped Q4 losses per share expectations on Wall Street. The Billerica, Mass.-based company posted losses of $11.9 million, or 27¢ per share, on sales of $20.5 million for the 3 months ended December 31, seeing losses shrink 24.7% while sales shrunk a smaller 4.4% compared with the same period during the previous year. Quarterly losses-per-share were just ahead of the 31¢ consensus on Wall Street. For the full fiscal year, ConforMIS p...
Source: Mass Device - February 8, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News MassDevice Earnings Roundup Wall Street Beat conformis Source Type: news

Surmodics misses sales estimates in Q1
Shares in Surmodics (NSDQ:SRDX) fell slightly today after the medical device maker missed expectations on Wall Street with its first quarter results. The Eden Prairie, Minn.-based company swung to a net loss of -$1.5 million on sales of $17.0 million for the 3 months ended Dec. 31, for a sales loss of -4% compared with the same period last year. Get the full story at our sister site, Drug Delivery Business News. The post Surmodics misses sales estimates in Q1 appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - February 8, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations MassDevice Earnings Roundup Pharmaceuticals Vascular Wall Street Beat SurModics Inc. Source Type: news

Cardinal Health ’ s Q2 profit surges on medical supplies acquisition, tax reform
Fiscal second-quarter profits for Cardinal Health (NYSE:CAH) surged at a triple-digit clip, fueled by contributions from the medical supplies business it bought from Medtronic (NYSE:MDT) for $6 billion last year. Dublin, Ohio-based Cardinal posted profits of $1.05 billion, or $3.33 per share, on sales of $35.19 billion for the three months ended Dec. 31, 2017. That amounts to profit growth of 225% on sales growth of 6.1% compared with fiscal Q2 2017. Adjusted to exclude one-time items, including a 20¢-per-share net benefit from last year’s tax reforms, earnings per share were $1.51, a whopping 36¢...
Source: Mass Device - February 8, 2018 Category: Medical Devices Authors: Brad Perriello Tags: MassDevice Earnings Roundup Wall Street Beat Cardinal Health Source Type: news

Cardiovascular Systems shares dip on mixed-bag Q2
Shares in Cardiovascular Systems (NSDQ:CSII) fell today after the medical device maker posted growing losses, despite having topped loss-per-share consensus on Wall Street with its second quarter earnings results. The St. Paul, Minn.-based company posted losses of $413,000, or 1¢ per hare, on sales of $52.6 million for the three months ended December 31, seeing losses grow 139.6% while sales grew by 5.2% compared with the same period last year. Losses per share were just ahead of the 4¢ consensus on Wall Street, while sells fell just short of the $53.3 million analyst’s expectations. “We are enco...
Source: Mass Device - February 8, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News MassDevice Earnings Roundup Wall Street Beat Cardiovascular Systems Inc. Source Type: news

Tax revision pushes Edwards Lifesciences into Q4 red
Edwards Lifesciences (NYSE:EW) revised its books based on new tax rules on repatriating foreign profits that went into effect last year, leading to a swing to losses for the fourth quarter and modest growth for the full year. The charges, amounting to a $326.7 million Q4 charge and $451.3 million for 2017, left the replacement heart valve maker’s sales and adjusted earnings untouched. Edwards had reported the charges as $288.2 million and $412.8 million, respectively. The Irvine, Calif.-based company originally posted Q4 profits of $35.7 million, or 17¢ per share, on sales of $888.5 million, for a...
Source: Mass Device - February 8, 2018 Category: Medical Devices Authors: Brad Perriello Tags: MassDevice Earnings Roundup Replacement Heart Valves Wall Street Beat Edwards Lifesciences Source Type: news

Regeneron profit beats estimates on strong sales of key drugs
(Reuters) - U.S. drugmaker Regeneron Pharmaceuticals Inc's quarterly profit and revenue beat estimates, helped by strong demand for its new eczema drug Dupixent and its flagship eye treatment Eylea. (Source: Reuters: Health)
Source: Reuters: Health - February 8, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Regeneron profit beats on higher sales
(Reuters) - Regeneron Pharmaceuticals Inc's quarterly profit beat estimates on Thursday, helped by higher sales including flagship eye treatment Eylea. (Source: Reuters: Health)
Source: Reuters: Health - February 8, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

LabCorp's 4Q earnings get a boost from tax bill
The new U.S. tax law boosted Laboratory Corporation of American Holdings' fourth-quarter earnings, with the Burlington company posting a profit of $706.8 million on Tuesday. LabCorp's (NYSE: LH) earnings for the fourth quarter were up from $184.4 million in 2016. Per-share earnings were $6.81, up from $1.75 during the same period a year ago. LabCorp said it saw a $519 million or $5-per-share benefit in earnings as a result of the tax bill signed in December, which " resulted in favorable re-valuation… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - February 7, 2018 Category: American Health Authors: Jessica Seaman Source Type: news

Haemonetics shares rise on Q3 beat
Shares in Haemonetics (NYSE:HAE) rose today after the medical device maker beat expectations on Wall Street with its third quarter results. The Braintree, Mass.-based company posted losses of $6.5 million, or 12¢ per share, on sales of $234 million for the 3 months ended December 30, seeing the bottom line shrink 142.5% while sales grew 2.7% compared with the same period last year. Adjusted to exclude one-time items, earnings per share were 62¢, well above the 44¢ consensus on Wall Street where analysts hoped to see sales of $226.9 million, which the company also topped. “Our strategy is working a...
Source: Mass Device - February 6, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News MassDevice Earnings Roundup Wall Street Beat Haemonetics Source Type: news

GE Healthcare launches analytics program for PyeongChang, Tokyo Olympic athletes
General Electric (NYSE:GE) said yesterday it is supplying a bespoke advanced analytics solution for both the Olympic Winter Games in PyeongChang this year and the Olympic Games in Tokyo in 2020. The system, designed through a partnership with the International Olympic Committee, integrates athlete information including injuries and illness alongside venue, sport and training procedures to produce more informed treatment decisions and improve health and safety at the games. “Through digital transformation, the IOC is pursuing its mission of helping to prevent injuries among our world-class athletes. With 40 ...
Source: Mass Device - February 6, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Software / IT GE Healthcare Source Type: news

Allergan's profit beats; migraine drug succeeds in key study
(Reuters) - Allergan Plc on Tuesday reported a better-than-expected quarterly profit on strong demand for Botox, and said its migraine treatment met the main goals in a late-stage study. (Source: Reuters: Health)
Source: Reuters: Health - February 6, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Becton Dickinson can ’ t escape global stock slide despite Q2 beats
Becton Dickinson (NYSE:BDX) couldn’t shake the nosedive in stock markets worldwide, despite posting fiscal second-quarter results that handily beat expectations in its first earnings release involving C.R. Bard. Franklin Lakes, N.J.-based BD swung to red ink for the three months ended Dec. 31, 2017, reporting losses of -$174 million, or -76¢ per share, on sales of $3.08 billion. That compares to profits of $562 million and sales growth of 5.4% compared with fiscal Q2 2016. Adjusted to exclude one-time items, including a $276 million increase in acquisition and restructuring costs and the impact of...
Source: Mass Device - February 6, 2018 Category: Medical Devices Authors: Brad Perriello Tags: MassDevice Earnings Roundup Wall Street Beat bectondickinson Source Type: news

Amgen swings to a loss in Q4 after $6B hit from tax reform
Shares in Amgen (NSDQ:AMGN) rose slightly today after the biotech missed expectations on Wall Street with its fourth-quarter earnings, but topped EPS estimates for the year ahead. The Thousand Oaks, Calif.-based company swung to a net loss in Q4 thanks to a $6 billion tax charge, posting -$4.26 billion on sales of $5.8 billion in the 3 months ended Dec. 31, for a sales loss of -3% compared with the same period last year. Get the full story at our sister site, Drug Delivery Business News. The post Amgen swings to a loss in Q4 after $6B hit from tax reform appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - February 2, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Biotech Drug-Device Combinations MassDevice Earnings Roundup Pharmaceuticals Wall Street Beat Amgen Source Type: news

Boston Scientific confirms Lotus valve off the market until 2019
Boston Scientific (NYSE:BSX) CEO Mike Mahoney yesterday confirmed that the company’s entry into the transcatheter aortic valve market, Lotus, will remain off the market for the rest of the year. Last November news of another Lotus delay pared  $3 billion from Boston’s market capitalization. The Marlborough, Mass.-based company, which recalled the Lotus transcatheter aortic heart valve in February 2017 over issues with its locking mechanism, said it no longer expected the ensuing manufacturing and design specification changes to get the valve back on the market in Europe or allow th...
Source: Mass Device - February 2, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Replacement Heart Valves Wall Street Beat Boston Scientific Source Type: news

Tax overhaul charge hands Merck 4Q loss despite higher sales
Drug sales rise but Merck posts 4th-quarter loss of $872 million due to $2.6 B charge related to the U.S. tax overhaul (Source: ABC News: Health)
Source: ABC News: Health - February 2, 2018 Category: Consumer Health News Tags: Health Source Type: news

Edwards Lifesciences shares up after Q4, 2017 earnings beat The Street
Shares in Edwards Lifesciences (NYSE:EW) have risen in after-hours trading today after the medical device maker beat expectations on Wall Street with its fourth quarter and full fiscal 2017 earnings results. The Irvine, Calif.-based company posted sales of $35.7 million, or 17¢ per share, on sales of $888.5 million for the 3 months ended Dec. 31, seeing the bottom line shrink 77.5% while sales grew 15.7% compared with the same period during the previous year. Adjusted to exclude one-time items, earnings per share were 94¢, just ahead of the 91¢ consensus on Wall Street where analysts were expecting to s...
Source: Mass Device - February 1, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News MassDevice Earnings Roundup Wall Street Beat Edwards Lifesciences Source Type: news

Owens & Minor shares tumble on prelim 2017 earnings miss
Owens & Minor (NYSE:OMI) shares have fallen today after the company released preliminary results for its full fiscal year 2017 that missed analyst expectations on Wall Street. The Richmond, Va.-based company said it expects to post non-GAAP adjusted earnings per share of between $1.58 and $1.61 for the full year, with revenues between $9.2 billion and $9.3 billion. The numbers are just below the consensus released by analysts on Wall Street, who expected to see non-GAAP EPS of $1.78 for the year with sales of $9.4 billion. Owens & Minor said that performance during the fourth quarter of 2017 was “affecte...
Source: Mass Device - February 1, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Wall Street Beat Owens & Minor Source Type: news

Amgen Reports Fourth Quarter And Full Year 2017 Financial Results
Expects to Increase Investments in Growth, Including a New U.S. Manufacturing Plant Announces 2018 Guidance Additional $10 Billion of Share Repurchases Authorized THOUSAND OAKS, Calif., Feb. 1, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year 2017. Key results include: For the fourth quarter, total revenues decreased 3 percent versus the fourth quarter of 2016 to $5.8 billion. For the full year, total revenues decreased 1 percent to $22.8 billion. GAAP loss per share of $5.89 for the fourth quarter and GAAP earnings per share (EPS) of $2.69 fo...
Source: Amgen News Release - February 1, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

SPM in Real Life: Winter ‘18
NEW MEMBERS: Winter ’18 Brief bios/plugs for new members (extracted from the Introduce Yourself Connect Community) Daniel Warren (Rik), initial member of Sensogram Technologies business team. Responsibilities include evangelism, channel development and management.  The technology continually reads and wirelessly reports vital signs in a variety of wearable form factors. Complementing this are solutions serving those with higher fall risk. Brian Eastwood, a research analyst, with a background in writing, editing, and public speaking experience. Brian joined the Editorial Review Board of the Journal of Particip...
Source: Society for Participatory Medicine - February 1, 2018 Category: General Medicine Authors: Danny van Leeuwen Tags: Newsletter Source Type: news

Shares in Novo Nordisk sink after Q4 earnings, sales disappoint
Shares in Novo Nordisk (NYSE:NVO) fell today after the insulin-maker missed expectations on Wall Street with its fourth quarter and full-year financial results. The Denmark-based company posted profits of $1.38 billion on sales of $4.68 billion for the 3 months ended Dec. 31, for bottom-line loss of -5% on sales loss of -5% compared with the same period last year. Get the full story at our sister site, Drug Delivery Business News. The post Shares in Novo Nordisk sink after Q4 earnings, sales disappoint appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - February 1, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations MassDevice Earnings Roundup Pharmaceuticals Wall Street Beat Novo Nordisk Source Type: news

Conmed ’ s Q4, 2017 profits surge on tax gain
Fourth-quarter and full-year profits surged for ConMed (NSDQ:CNMD) thanks to the tax reforms passed last year, as the medical device maker posted Street-beating sales and earnings numbers. Utica, N.Y.-based Conmed yesterday reported profits of $46.7 million, or $1.65 per share, on sales of $222.6 million for the three months ended Dec. 31, 2017. That’s a whopping 596.1% addition to the bottom line on sales growth of 9.0% compared with Q4 2016, thanks to a $32.1 million tax benefit during the quarter. And even when you back out one-time items such as the tax benefit, adjusted earnings per share hit 69¢, 4&ce...
Source: Mass Device - February 1, 2018 Category: Medical Devices Authors: Brad Perriello Tags: MassDevice Earnings Roundup Wall Street Beat ConMed Corp. Source Type: news

Baxter posts Street-beating Q4 earnings, sales
Shares in Baxter (NYSE:BAX) fell slightly this morning after the company topped expectations on Wall Street with its fourth quarter and full-year results. The Deerfield, Ill.-based company swung to a loss in Q4 thanks to a $322 million hit from the recently-enacted U.S. tax reform legislation. Baxter posted -$71 million in net losses for the quarter on sales of $2.77 billion for the 3 months ended Dec. 31, for sales growth of 5% compared with the same period last year. Get the full story at our sister site, Drug Delivery Business News. The post Baxter posts Street-beating Q4 earnings, sales appeared first on Mass...
Source: Mass Device - February 1, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Hospital Care MassDevice Earnings Roundup Pharmaceuticals Surgical Wall Street Beat Baxter Source Type: news

Abiomed ’ s fiscal Q3 crushes The Street despite $19m tax hit
Abiomed (NSDQ:ABMD) topped the consensus forecast for its fiscal third-quarter results despite taking a nearly $19 million hit due to the tax reforms enacted last year. The Danvers, Mass.-based cardiac assist device maker posted profits of $13.4 million, or 29¢ per share, on sales of $154.0 million for the three months ended Dec. 31, 2017, for a bottom-line slide of -12.9% on sales growth of 34.3%. But excluding the $18.8 million tax reform hit, adjusted earnings per share were 70¢, 19¢ ahead of Wall Street, where analysts were looking for sales of $148.5 million. “It is an exciting time for the compan...
Source: Mass Device - February 1, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Cardiac Assist Devices MassDevice Earnings Roundup Wall Street Beat Abiomed Source Type: news

Boston Scientific slides to Q4 red on $861m tax charge
An estimated $861 million tax charge pushed Boston Scientific (NYSE:BSX) into the red during the fourth quarter and slashed full-year profits by 70%, but the medical device maker still managed to meet or beat Wall Street’s expectations. Marlborough, Mass.-based Boston Scientific posted losses of -$615 million, or -45¢ per share, on sales of $2.41 billion for the three months ended Dec. 31, 2017, compared with Q4 profits of $124 million, or 9¢ per share on sales growth of 9.9%. Adjusted to exclude one-time items including the tax sting, earnings per share were 34¢, dead in line with The Street, whe...
Source: Mass Device - February 1, 2018 Category: Medical Devices Authors: Brad Perriello Tags: MassDevice Earnings Roundup Wall Street Beat Boston Scientific Source Type: news

Eli Lilly beats the Street with Q4 earnings
Shares in Eli Lilly (NYSE:LLY) fell slightly this morning even though the pharmaceutical company beat analysts’ estimates with its fourth quarter and full-year financial results. The Indianapolis-based company swung to a net loss in the fourth quarter, posting -$1.7 billion, or $1.85 per share, on sales of $6.2 billion for the 3 months ended Dec. 31, for sales growth of 7% compared with the same period last year. Get the full story at our sister site, Drug Delivery Business News. The post Eli Lilly beats the Street with Q4 earnings appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - January 31, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes MassDevice Earnings Roundup Pharmaceuticals Wall Street Beat Eli Lilly & Co. Source Type: news

Tax reforms push Stryker to Q4 red
Stryker (NYSE:SYK) swung to red ink during the fourth quarter despite posting a nearly 10% top-line gain, largely due to the impact of the tax reforms passed last year. The Kalamazoo, Mich.-based medtech giant reported losses of -$249 million, or -66¢ per share, on sales of $3.47 billion for the three months ended Dec. 31, 2017. That compares with profits of $510 million, or $1.34 per share, for Q4 2016. Adjusted to exclude one-time items, earnings per share were $1.96, 2¢ ahead of the consensus on Wall Street, where analysts were looking for sales of $3.39 billion. Full-year profits were down -38.1% to $1.0...
Source: Mass Device - January 31, 2018 Category: Medical Devices Authors: Brad Perriello Tags: MassDevice Earnings Roundup Wall Street Beat Stryker Source Type: news

Siemens Healthineers taps ex-Abbott Vascular prez Nath to lead lab diag biz | Personnel Moves January 30, 2018
Siemens (NYSE:SI) Healthineers said today it tapped former Abbott (NYSE:ABT) Vascular president Dr. Deepak Nath as its new laboratory diagnostics business president, taking over for Franz Walt who operated as president from 2014 to 2017. Nath spent 10 years with Abbott, serving most recently as its vascular division president and as an executive officer of the company, and as president of the molecular diagnostics division prior to that. He also operated as GM of Ibis Biosciences, and has held positions at Amgen (NSDQ:AMGN) and McKinsey. “Siemens Healthineers seeks to benefit from market oppo...
Source: Mass Device - January 30, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Abbott aligntechnology Amgen Cardiovascular Systems Inc. CHF Solutions Inc. Cook Group Inc. Endologix Hill-Rom Holdings Inc. Invetech johnsonandjohnson lohmannandrauscher Medtronic Neuromod Devices Novar Source Type: news

Zimmer Biomet ’ s profits surge on tax gain
The tax reforms enacted last year created huge fourth-quarter and full-year profit gains for Zimmer Biomet (NYSE:ZBH), but the orthopedics giant still only managed to meet Wall Street’s earnings expectations despite logging sales beats for both periods. Warsaw, Ind.-based Zimmer Biomet posted profits of $1.26 billion, or $6.16 per share, on sales of $2.07 billion for the three months ended Dec. 31, 2017, for a whopping 1,706% bottom-line gain on sales growth of 3.0% compared with Q4 2016. Adjusted to exclude one-time items, earnings per share were $2.10, in line with The Street, where analysts were looking for s...
Source: Mass Device - January 30, 2018 Category: Medical Devices Authors: Brad Perriello Tags: MassDevice Earnings Roundup Orthopedics Wall Street Beat zimmerbiomet Source Type: news